doi: 10.1177/0960327120937329 129 AhmedZAAbtarANOthmanHHAzizTA
Research Institute of Nephrology, Zhengzhou University, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, P
CrossRef Extremely low risk of hepatocellular carcinoma development in patients with chronic hepatitis B in immunetolerant phase Han Ah Lee, Hyun Woong Lee, In Hee Kim, Soo Young Park, Dong Hyun Sinn, Jung Hwan Yu, Yeon Seok Seo, Soon Ho Um, Jung Il Lee, Kwan Sik Lee, Chang Hun Lee, Won Young Tak, Young Oh Kweon, Wonseok Kang, YongHan Paik, JinWoo Lee, Sang Jun Suh, Young Kul Jun Alimentary Pharmacology & Therapeutics .2020
Laboratory Investigations Level 1: Renal function, LFT, Proteinuria, Complete blood count, troponin, NT-Pro BNP, Ferritin, Iron, Calcium, Phosphate, Thyroid hormone levels, serum free light chain assay, and urine/serum protein immunofixation (only in case of suspected RCM)Class IC [] Level 2: Viral serology, organ-specific and non-organ-specific investigations, lactic acid, myoglobin, carnitine profile, alpha-galactosidase, thiamine, serum ACE, PTH, free fatty acidsClass II [] Holter: Ventricular tachycardias, nonsustained VTs, heart blocks, atrial arrhythmias MRI: Class I [] contrast CMR during the initial evaluation, ClassIIa [] during monitoring for disease progression or risk stratification for SCD, to assess for therapeutic response in cardiac amyloidosis, hemochromatosis, Anderson Fabry disease, sarcoid, and other inflammatory cardiomyopathies, in family screening genotype positive-phenotype negative to aid early detection and diagnosis
